**Core Concept**
Chronic Myeloid Leukemia (CML) is a type of myeloproliferative neoplasm characterized by the uncontrolled proliferation of mature and immature granulocytes in the bone marrow. The disease is often associated with a chromosomal abnormality known as the Philadelphia chromosome, which results from a reciprocal translocation between chromosomes 9 and 22.

**Why the Correct Answer is Right**
The correct answer is related to the pathophysiology of CML. The Philadelphia chromosome is formed by the fusion of the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9, resulting in the creation of a novel BCR-ABL1 fusion gene. This fusion gene encodes a constitutively active tyrosine kinase that drives the proliferation of leukemic cells. The BCR-ABL1 fusion protein is a key molecular abnormality in CML and is targeted by tyrosine kinase inhibitors (TKIs) such as imatinib.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because CML is not typically associated with a high risk of acute transformation to acute myeloid leukemia (AML).
**Option B:** This option is incorrect because the Philadelphia chromosome is a specific chromosomal abnormality that is diagnostic of CML, but it is not the only genetic abnormality associated with the disease.
**Option C:** This option is incorrect because CML is not typically characterized by a strong association with a specific age group or demographic.

**Clinical Pearl / High-Yield Fact**
The Philadelphia chromosome is a hallmark of CML and is detectable in the majority of patients with the disease. This chromosomal abnormality is a critical diagnostic feature of CML and is often used to differentiate it from other myeloproliferative neoplasms.

**Correct Answer: B. The Philadelphia chromosome is a diagnostic feature of CML.**